RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1500

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00

RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE: LLY) with a Outperform and raises the price target from $1250 to $1500.